See more : Shuz Tung Machinery Industrial Co., Ltd. (4537.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Lionco Pharmaceutical Group Co.,Ltd. (603669.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lionco Pharmaceutical Group Co.,Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- PT Bangun Karya Perkasa Jaya Tbk (KRYA.JK) Income Statement Analysis – Financial Results
- Gaussin SA (ALGAU.PA) Income Statement Analysis – Financial Results
- Kavveri Telecom Products Limited (KAVVERITEL.NS) Income Statement Analysis – Financial Results
- New Age Metals Inc. (NAM.V) Income Statement Analysis – Financial Results
- Línea Directa Aseguradora, S.A. (LNDAF) Income Statement Analysis – Financial Results
Lionco Pharmaceutical Group Co.,Ltd. (603669.SS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.lingkang.com.cn
About Lionco Pharmaceutical Group Co.,Ltd.
Lionco Pharmaceutical Group Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in China. The company offers nutrition, antimicrobial, antiviral, digestion, cardiovascular, detoxification, anti-tumor, and other products. It also operates research institutes that specialize in the research of chemical drugs, natural medicines, and biological drugs. Lionco Pharmaceutical Group Co., Ltd. was founded in 2003 and is based in Shannan, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 196.83M | 289.26M | 740.33M | 1.00B | 1.64B | 1.67B | 1.01B | 478.59M | 550.64M | 576.40M | 494.25M | 468.28M | 271.55M |
| Cost of Revenue | 104.97M | 93.12M | 152.69M | 155.65M | 223.16M | 201.99M | 200.79M | 202.62M | 220.15M | 225.43M | 202.08M | 181.10M | 149.60M |
| Gross Profit | 91.86M | 196.15M | 587.64M | 845.35M | 1.41B | 1.47B | 804.29M | 275.97M | 330.50M | 350.97M | 292.17M | 287.18M | 121.95M |
| Gross Profit Ratio | 46.67% | 67.81% | 79.38% | 84.45% | 86.35% | 87.90% | 80.02% | 57.66% | 60.02% | 60.89% | 59.11% | 61.33% | 44.91% |
| Research & Development | 29.12M | 31.63M | 22.77M | 20.36M | 38.04M | 24.30M | 47.40M | 29.34M | 38.58M | 36.77M | 42.98M | 42.76M | 0.00 |
| General & Administrative | 16.31M | 13.17M | 16.59M | 18.23M | 17.82M | 17.93M | 22.57M | 31.03M | 31.46M | 26.65M | 18.16M | 29.23M | 33.13M |
| Selling & Marketing | 112.79M | 236.62M | 423.91M | 624.51M | 1.09B | 1.22B | 538.86M | 54.39M | 55.66M | 79.00M | 69.14M | 60.11M | 22.24M |
| SG&A | 129.10M | 249.79M | 440.50M | 642.74M | 1.11B | 1.23B | 561.43M | 85.41M | 87.13M | 105.66M | 87.30M | 89.34M | 55.37M |
| Other Expenses | 82.62M | 78.85M | 54.74M | -11.10M | 38.11M | -4.82M | -1.84M | 48.64M | 6.35M | 21.83M | 23.02M | 10.72M | 7.06M |
| Operating Expenses | 240.85M | 360.26M | 518.02M | 652.00M | 1.19B | 1.27B | 635.66M | 164.10M | 170.20M | 186.55M | 163.06M | 159.21M | 57.65M |
| Cost & Expenses | 345.81M | 453.38M | 670.70M | 807.66M | 1.41B | 1.47B | 836.45M | 366.71M | 390.35M | 411.98M | 365.13M | 340.31M | 207.24M |
| Interest Income | 3.31M | 7.11M | 9.30M | 7.63M | 4.46M | 2.86M | 2.55M | 2.76M | 3.95M | 2.28M | 1.16M | 715.67K | 0.00 |
| Interest Expense | 3.71M | 5.83M | 15.51M | 11.25M | 13.59M | 2.22M | 147.37K | 457.82K | 4.78M | 192.50K | 125.39K | 100.20K | 0.00 |
| Depreciation & Amortization | 49.45M | 49.36M | 48.15M | 45.67M | 41.34M | 34.99M | 34.81M | 31.95M | 24.21M | 24.40M | 11.70M | 15.98M | -2.11M |
| EBITDA | -90.79M | -134.37M | 132.72M | 251.86M | 288.78M | 249.41M | 215.06M | 209.77M | 208.30M | 201.19M | 141.65M | 142.61M | 63.29M |
| EBITDA Ratio | -46.13% | -41.92% | 18.53% | 23.70% | 16.72% | 14.42% | 21.72% | 43.58% | 38.55% | 37.06% | 28.66% | 31.69% | 23.31% |
| Operating Income | -148.98M | -164.12M | 71.13M | 180.75M | 222.63M | 209.01M | 181.94M | 130.62M | 172.35M | 163.90M | 130.00M | 124.21M | 65.40M |
| Operating Income Ratio | -75.69% | -56.74% | 9.61% | 18.06% | 13.62% | 12.52% | 18.10% | 27.29% | 31.30% | 28.44% | 26.30% | 26.52% | 24.08% |
| Total Other Income/Expenses | -1.97M | -130.52K | -648.31K | -1.49M | 298.78K | -4.82M | -1.84M | 48.64M | 4.26M | 21.13M | 23.00M | 10.72M | 7.06M |
| Income Before Tax | -150.95M | -188.81M | 70.48M | 179.26M | 222.92M | 204.19M | 180.10M | 177.17M | 176.61M | 185.03M | 153.00M | 134.93M | 72.46M |
| Income Before Tax Ratio | -76.69% | -65.27% | 9.52% | 17.91% | 13.63% | 12.23% | 17.92% | 37.02% | 32.07% | 32.10% | 30.96% | 28.81% | 26.69% |
| Income Tax Expense | 540.84K | 6.94M | 4.58M | 19.19M | 21.33M | 21.49M | 19.10M | 23.24M | 26.92M | 35.17M | 38.20M | 39.75M | 16.73M |
| Net Income | -151.50M | -195.75M | 65.90M | 160.07M | 201.59M | 182.70M | 161.01M | 153.93M | 149.69M | 149.86M | 114.80M | 95.17M | 55.75M |
| Net Income Ratio | -76.97% | -67.67% | 8.90% | 15.99% | 12.33% | 10.94% | 16.02% | 32.16% | 27.19% | 26.00% | 23.23% | 20.32% | 20.53% |
| EPS | -0.21 | -0.27 | 0.09 | 0.22 | 0.28 | 0.26 | 0.22 | 0.22 | 0.23 | 0.28 | 0.22 | 0.18 | 0.41 |
| EPS Diluted | -0.21 | -0.27 | 0.09 | 0.21 | 0.28 | 0.26 | 0.22 | 0.22 | 0.23 | 0.28 | 0.22 | 0.18 | 0.41 |
| Weighted Avg Shares Out | 721.41M | 718.45M | 715.37M | 713.44M | 713.44M | 710.51M | 713.44M | 713.44M | 639.12M | 534.04M | 533.91M | 532.89M | 721.23M |
| Weighted Avg Shares Out (Dil) | 721.41M | 718.45M | 774.42M | 762.25M | 713.44M | 710.51M | 717.21M | 715.88M | 641.81M | 534.04M | 533.91M | 532.97M | 721.23M |
Source: https://incomestatements.info
Category: Stock Reports